Article info
PDFEditorial
The UK Risk-Sharing Scheme for interferon-beta and glatiramer acetate in multiple sclerosis. Outcome of the year-6 analysis
- Correspondence to Dr Martin Duddy, Department of Neurology, Newcastle upon Tyne Hospitals Trust, Queen Victoria Road, Newcastle upon Tyne NE1 4LP, UK; martin.duddy{at}nuth.nhs.uk
Citation
The UK Risk-Sharing Scheme for interferon-beta and glatiramer acetate in multiple sclerosis. Outcome of the year-6 analysis
Publication history
- Accepted September 8, 2015
- First published October 1, 2015.
Online issue publication
April 14, 2016
Article Versions
- Previous version (14 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Other content recommended for you
- Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme
- UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model
- ▼Natalizumab for multiple sclerosis?
- Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator
- The unintended consequences of NICE
- NICE and neurology
- Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial
- Diagnosis and disease modifying treatments in multiple sclerosis
- Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis
- Disease modifying therapies for relapsing multiple sclerosis